

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM485210

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
REGULUS THERAPEUTICS INC.		08/06/2018	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER		
<b>Street Address:</b>	133 NORTH FAIRFAX STREET		
<b>City:</b>	ALEXANDRIA		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22314		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5354626	REGULUS	
<b>Serial Number:</b>	87028238	REGULUS	
<b>Registration Number:</b>	5102108	REGULUS MICROMARKERS	
<b>Registration Number:</b>	4795763	REGULUS THERAPEUTICS	
<b>Serial Number:</b>	87285492	REGULUS THERAPEUTICS	
<b>Registration Number:</b>	4422167	REGULUS THERAPEUTICS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6785532602		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6785532601		
<b>Email:</b>	jimmarl@gtlaw.com		
<b>Correspondent Name:</b>	LaShana C. Jimmar, Paralegal		
<b>Address Line 1:</b>	Greenberg Traurig, LLP		
<b>Address Line 2:</b>	3333 Piedmont Road, NE, Suite 2500		
<b>Address Line 4:</b>	Atlanta, GEORGIA 30305		
<b>ATTORNEY DOCKET NUMBER:</b>	138179.015200		
<b>NAME OF SUBMITTER:</b>	LaShana C. Jimmar		
<b>SIGNATURE:</b>	/LaShana C. Jimmar/		

CH \$165.00 5354626

**DATE SIGNED:**

08/08/2018

**Total Attachments: 23**

source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page1.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page2.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page3.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page4.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page5.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page6.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page7.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page8.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page9.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page10.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page11.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page12.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page13.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page14.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page15.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page16.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page17.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page18.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page19.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page20.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page21.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page22.tif  
source=OXFORD - REGULUS THERAPEUTICS INC. - Intellectual Property Security Agreement#page23.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as August 6, 2018, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “**Lender**” and collectively, the “**Lenders**”), and REGULUS THERAPEUTICS INC., a Delaware corporation with offices located at 10614 Science Center Dr., San Diego, California 92121 (“**Grantor**”).

### RECITAL

A. Lenders agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Amended and Restated Loan and Security Agreement by and among the Collateral Agent, Lenders and Grantor dated as of June 17, 2016 (as the same may be, and may have been, amended, modified or supplemented from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). In accordance with the terms of the Loan Agreement, as amended by that certain third amendment thereto, dated as of the date hereof, Grantor is granting to Collateral Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks and Patents (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, effective as of the date hereof, Grantor hereby grants and pledges to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “**Intellectual Property Collateral**”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “**Copyrights**”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”); provided, however that Trademarks shall not include any intent-to-use trademarks;

(f) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(g) All licenses or other rights to use any of the Copyrights, Patents or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(h) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

(i) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Grantor hereby represents and warrants that the Copyrights set forth on Exhibit A, the Patents set forth on Exhibit B and the Trademarks set forth on Exhibit C include all Copyrights, Patents and Trademarks of Grantor and its Subsidiaries that are either registered, or for which applications for registration or grant, as applicable, are pending, on the date hereof. Grantor hereby covenants to provide prompt notice of (A) any material change in the composition of the Intellectual Property, and (B) any new the Copyrights, Trademarks or Patents of Grantor or any of its Subsidiaries that are either registered or for which an application for registration or grant is filed.


This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the ratable benefit of the Lenders under the Loan Agreement, and shall become effective upon the date hereof. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Collateral Agent, of any or all other rights, powers or remedies.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

REGULUS THERAPEUTICS INC.

By   
Name: DANIEL CHEVALIER  
Title: CHIEF FINANCIAL OFFICER

**COLLATERAL AGENT AND LENDER:**

OXFORD FINANCE LLC

By \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

REGULUS THERAPEUTICS INC.

By \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

**COLLATERAL AGENT AND LENDER:**

OXFORD FINANCE LLC


By   
Name: Colette H. Heatherly  
Title: Senior Vice President

EXHIBIT A

Copyrights

Description

Registration/  
Application  
Number

Registration/  
Application  
Date

None.

EXHIBIT B

Patents

*Please see attached*



Regulus Patent Portfolio  
July 26, 2018

Regulus Ref. (*see notes column)	Effective Filing Date	Priority Date	Title	CC	Status	Serial Number	Patent Number	Issue Date	Publication #	Publication Date	Notes
REG-0001CA	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	CA	FILED	2533701			2533701	17-Feb-05	
REG-0001EP	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	EP	FILED	04780181.6			1648914	26-Apr-06	
REG-0001EP.D1	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	EP	GRANTED	12173039.4	2530157	28-Sep-16	2530157	5-Dec-12	
REG-0001IL	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	IL	GRANTED	173364	173364	1-May-17	173364	11-Jun-06	
REG-0001IL.2	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	IL	FILED	242135					
REG-0001US*	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	10/909,125	7683036	23-Mar-10	20050261218	24-Nov-05	Maintenance to be discontinued; drop dead date 3/23/2022
REG-0001US.C10	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	14/705,580	9,267,138	23-Feb-16	2015-0337305	26-Nov-15	
REG-0001US.C11	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	14/804,952	9,663,787	30-May-17			
REG-0001US.C12	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	15/234,487	9,752,146	5-Sep-17	2017-0037402	9-Feb-17	
REG-0001US.C14	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	FILED	15/479,072			2017-0268002	21-Sep-17	
REG-0001US.C15	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	FILED	15/664,005			2018-0010128	11-Jan-18	
REG-0001US.C2	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	12/345,854	8,765,701	2-Jul-14	20090291906	26-Nov-09	
REG-0001US.C3	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	12/345,891	8,133,876	13-Mar-12	20090291907	26-Nov-09	

TRADEMARK

REEL: 006407 FRAME: 0442

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0001US.C4	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	13/359,271	8,546,350	1-Oct-13	20120122216	17-May-12
REG-0001US.C5	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	13/412,307	8,946,179	3-Feb-15	20120157514	21-Jun-12
REG-0001US.C6	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	13/540,097	8,809,294	19-Aug-14	20120283319	8-Nov-12
REG-0001US.C7	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	14/011,808	9,447,412	20-Sep-16	20140057963	27-Feb-14
REG-0001US.C9	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	14/703,610	9,447,413	20-Sep-16	2015-0337304	26-Nov-15
REG-0001US.D1	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	12/345,725	8,697,663	15-Apr-14	20090317907	24-Dec-09
REG-0001US.D2	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	12/345,780	8,178,506	15-May-12	20090298174	3-Dec-09
REG-0001US.D3	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	12/346,919	8,110,558	7-Feb-12	20110224277	15-Sep-11
REG-0001US.D4	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	12/346,940	8,106,025	31-Jan-12	20100267813	21-Oct-10
REG-0001US.D6	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	14/143,943	8,859,521	14-Oct-14	2014-0121364	1-May-14
REG-0001US.D7	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	14/245,541	9,139,832	22-Sep-15	2014-0336370	13-Nov-14
REG-0001US.D8	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS	US	GRANTED	14/245,535	9,528,108	27-Dec-16	2014-0329882	6-Nov-14
REG-0001US.P2	30-Jul-04	31-Jul-03	OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR THE USE IN MODULATION OF PRI-MIRNAS	US	GRANTED	12/797,643	8,466,120	18-Jun-13	20100249215	30-Sep-10
REG-0002AU	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	AU	GRANTED	2006284855	2006284855	25-Jan-12	2006284855	8-Mar-07

Regulus Patent Portfolio  
July 26, 2018

REG-0002AU2*	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	AU	GRANTED	2011254085	2011254085	14-Feb-13	2011254085	19-Jan-12	Maintenance to be discontinued; drop dead date 2/28/2020
REG-0002AU3	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	AU	GRANTED	2013200489	2013200489	7-Jan-16	2013200489	21-Feb-13	
REG-0002CA	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	CA	GRANTED	2620856	2620856	28-Nov-17	2620856	8-Mar-07	
REG-0002EP*	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	EP	GRANTED	06813949.2	1931782	5-Jan-11	1931782	18-Jun-08	Maintenance to be discontinued; GB, IE, drop dead date 2/28/2019; DE, FR, CH drop dead date 2/28/2020
REG-0002EP.D1*	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	EP	GRANTED	10184811.7	2338991	18-Jan-17	2338991	29-Jun-11	Maintenance to be discontinued; drop dead date 2/28/2020
REG-0002JP*	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	JP	GRANTED	2008-529232	5523705	18-Apr-14	2008529232	12-Feb-09	Maintenance to be discontinued; drop dead date 10/18/2019
REG-0002US*	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	US	GRANTED	11/513,102	8,969,314	3-Mar-15	20070049547	1-Mar-01	Maintenance to be discontinued; drop dead date 3/3/2019
REG-0002US2	29-Aug-06	29-Aug-05	METHODS FOR USE IN MODULATING MIR-122a	US	GRANTED	14/596,822	9,994,842	12-Jun-18	20150232841	20-Aug-15	
REG-0003AU	29-Oct-08	29-Oct-07	TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER	AU	GRANTED	2008318778	2008318778	15-Jan-15	2008318778	7-May-09	
REG-0003IL	29-Oct-08	29-Oct-07	TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER	IL	GRANTED	205307	205307	30-Jan-16	205307	30-Dec-10	
REG-0003JP	29-Oct-08	29-Oct-07	TARGETING MICRORNAS FOR THE TREATMENT OF LIVER CANCER	JP	GRANTED	2010-532219	5535076	9-May-14	2011501962	20-Jan-11	
REG-0012US*	26-Feb-09	26-Feb-08	MICRORNA DETECTION	US	GRANTED	12/393,523	7,998,677	16-Aug-11	20090236225	24-Sep-09	Maintenance to be discontinued; drop dead date 8/16/2019
REG-0022US	22-Jul-11	23-Jul-10	TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS	US	GRANTED	13/811,423	8,815,826	26-Aug-14	20130184217	18-Jul-13	
REG-0022US.C1	22-Jul-11	23-Jul-10	TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS	US	GRANTED	14/334,872	9,181,548	10-Nov-15	20150080453	19-Mar-15	
REG-0022US.C2	22-Jul-11	23-Jul-10	TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS	US	GRANTED	14/872,564	9,556,435	31-Jan-17	2016-0108397	21-Apr-16	
REG-0022US.C3	22-Jul-11	23-Jul-10	TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS	US	GRANTED	15/380,629	9,970,007	15-May-18	2017-0198289	13-Jul-17	
REG-0022US.C4	22-Jul-11	23-Jul-10	TARGETING MICRORNAS FOR THE TREATMENT OF FIBROSIS	US	FILED	15/954,059					
REG-0025AU	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	AU	GRANTED	2012249851	2012249851	21-Sep-17	2012249851	1-Nov-12	
REG-0025AU2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	AU	FILED	2017219156					
REG-0025BR	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	BR	FILED	11 2013 027187 6				6-Jun-17	

TRADE MARK

REEL: 006407 FRAME: 0444

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0025CA	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CA	FILED	2833615	2833615			17-Oct-13
REG-0025CL	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CL	FILED	03105-2013				1-Aug-14
REG-0025CN	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CN	FILED	201280031285.4		CN103620035		5-Mar-14
REG-0025CO	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CO	GRANTED	13-257480	31152		15-May-17	
REG-0025CO2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CO	GRANTED	16-026442	33826		17-May-18	
REG-0025DZ	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	DZ	GRANTED	130714	8770		3-Aug-15	
REG-0025EA	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EA	GRANTED	201391492	025894		28-Feb-17	
REG-0025EP	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EP	GRANTED	12718549.4	2702155		1-Feb-17	14-Mar-14
REG-0025EP2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EP	FILED	17153724.4		3211082		30-Aug-17
REG-0025GC	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	GC	FILED	2012/21118				
REG-0025HK	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	HK	GRANTED	14109010.1	1195585		9-Mar-18	14-Nov-14
REG-0025HK2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	HK	FILED	18102629.5				
REG-0025ID	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	ID	FILED	W00 2013 05374		2014/05041		11-Dec-14
REG-0025IL	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	IL	FILED	229032				
REG-0025IN	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	IN	FILED	9840/DELNP/2013		9840/DELNP/2013 A		27-May-16
REG-0025IP	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	JP	GRANTED	2014-508494	6320292		13-Apr-18	7-Aug-14
REG-0025IP2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	JP	FILED	2018-070694				
REG-0025KR	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	KR	FILED	10-2013-7031227				
REG-0025MA	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	MA	GRANTED	PV/36437	35151		2-Jun-14	
REG-0025MX	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	MX	FILED	MX/A/2013/012452				
REG-0025MY	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	MY	FILED	PI 2013003885				

TRADE MARK

REEL: 006407 FRAME: 0445

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0025MY2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	NY	FILED	PI 2017000706					
REG-0025NZ	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	NZ	GRANTED	616748	616748	1-Jul-16			
REG-0025NZ2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	NZ	GRANTED	717921	717921	4-Jan-18			
REG-0025NZ3*	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	NZ	FILED	732274					Prosecution to be discontinued; drop dead deadline 1/21/2019
REG-0025PH	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	PH	FILED	1-2013-502199				27-Jan-14	
REG-0025SG	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	SG	FILED	201307945-4					
REG-0025TH	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	TH	FILED	1301006081					
REG-0025TW	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	TW	GRANTED	101114636	1607016	1-Dec-17	201300404	1-Jan-13	
REG-0025TW2*	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	TW	FILED	106131684			201811812	1-Apr-18	Prosecution to be discontinued; no drop dead date
REG-0025UA	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	UA	GRANTED	A201312414	115652	11-Dec-17			
REG-0025US2	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	14/111,976	9,181,547	10-Nov-15	2014-0107183	17-Apr-14	
REG-0025US3	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	14/444,406	8,912,161	16-Dec-14	2014-0329887	6-Nov-14	
REG-0025US4	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	14/883,055	9,790,496	17-Oct-17	2016-0138016	19-May-16	
REG-0025US5	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	FILED	15/704,749			2018-0155719	7-Jun-18	
REG-0025VN	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	VN	FILED	1-2013-03571					
REG-0025ZA	25-Apr-12	25-Apr-11	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	ZA	GRANTED	2013/08670	2013/08670	28-Apr-16			
REG-0036AR	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	AR	FILED	PI 13 01 01370			AR 090825 A1	10-Dec-14	
REG-0036AU	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	AU	FILED	2013251696					
REG-0036BR	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	BR	FILED	11 2014 026639 5					
REG-0036CA	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CA	FILED	2869639	2869639			3-Oct-14	
REG-0036CL	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CL	FILED	02844-2014			2014002844	13-Feb-15	

TRADE MARK

REEL: 006407 FRAME: 0446

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0036CL2	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CL	FILED	01195-2017					
REG-0036CN	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CN	FILED	201380020336.8	CN 104254607				31-Dec-14
REG-0036CO	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CO	GRANTED	14-238778	1303C	21-Mar-17	31163		10-Nov-14
REG-0036CR	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	CR	FILED	2014-0524					
REG-0036DO	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	DO	FILED	P2014-0233	DOP20140233				31-Dec-14
REG-0036DZ	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	DZ	FILED	140605					
REG-0036EA	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EA	FILED	2014491953					
REG-0036EC	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EC	FILED	IEPI-2014-28612					
REG-0036EG	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EG	FILED	PCT/1687/2014					
REG-0036EP	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EP	FILED	13720699.1	2841579				4-Mar-15
REG-0036GC	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	GC	FILED	2013/24201					
REG-0036GT	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	GT	FILED	A-2014-0221					17-Jan-18
REG-0036HK	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	HK	FILED	15107699.2	1207115				22-Jan-16
REG-0036ID	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	ID	FILED	P00201406548	2016/01881				25-Mar-16
REG-0036IL	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	IL	FILED	234904					
REG-0036IN	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	IN	FILED	9134/DELNP/2014					22-May-15
REG-0036JP	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	JP	GRANTED	2015-509097	2015-519891	13-Apr-18	6322189		16-Jul-15
REG-0036KR	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	KR	FILED	10-2014-7032508	20150003846				9-Jan-15
REG-0036MA	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	MA	GRANTED	37563	35962	1-Dec-14			
REG-0036MX	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	MX	GRANTED	MX/a/2014/012476	353562	17-Jan-18	2014012476		8-Dec-14
REG-0036MY	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	MY	FILED	PI 2014003019					

TRADE MARK

REEL: 006407 FRAME: 0447

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0036NG	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	NG	GRANTED	NG/PT/C/2014/620	NG/PT/C/2014/620	10-May-17		
REG-0036NZ	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	NZ	GRANTED	630591	630591	25-May-17		
REG-0036OA	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	OA	GRANTED	1201400479	17147	31-Jul-15		
REG-0036PA	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	PA	FILED	90396			28-Dec-15	
REG-0036PE	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	PE	FILED	001895-2014/DIN	24042014		2-Feb-15	
REG-0036PH	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	PH	FILED	1-2014-502387			22-Dec-14	
REG-0036SG	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	SG	GRANTED	11201406931X	11201406931X	2-Mar-17		
REG-0036TH	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	TH	FILED	1401006392		175918	17-May-18	
REG-0036TN	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	TN	GRANTED	TN2014/0401	24132	25-Feb-16	21-Dec-15	
REG-0036TW	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	TW	FILED	102114690		201345918	16-Nov-13	
REG-0036UA	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	UA	FILED	2014 12637				
REG-0036US	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	13/869,177	8,969,317	3-Mar-15	31-Oct-13	
REG-0036US2	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	14/597,676	9,267,137	23-Feb-16	6-Aug-15	
REG-0036US3	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	14/995,432	9,688,985	27-Jun-17	25-Aug-16	
REG-0036US4	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	15/441,590	9,970,009	15-May-18	24-Aug-17	
REG-0036US5	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	FILED	15/954,159				
REG-0036VN	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	VN	FILED	1-2014-03590				
REG-0036ZA	24-Apr-13	25-Apr-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	ZA	GRANTED	2014/07228	2014/07228	31-May-17		
REG-0037AR	8-Oct-13	9-Oct-12	SYNDROME	AR	FILED	20130103643				
REG-0037AU	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	AU	FILED	2013329427			8-Aug-17	
REG-0037BR	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	BR	FILED	BR1120150077099				

TRADE MARK

REEL: 006407 FRAME: 0448

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0037CA	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	CA	FILED	2885605							
REG-0037CL	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	CL	FILED	00873-2015						14-Aug-15	
REG-0037CN	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	CN	FILED	201380051249.9					104718295	17-Jun-15	
REG-0037CR	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	CR	FILED	2015-0236							
REG-0037DZ	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	DZ	GRANTED	150151	9621					12-Oct-17	
REG-0037EA	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	EA	FILED	201590711							
REG-0037EG*	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	EG	FILED	PCT 518/2015						30-Jul-15	Prosecution to be discontinued; drop dead date 10/8/2018
REG-0037EP	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	EP	FILED	13777458.4					2906698	19-Aug-15	
REG-0037GC	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	GC	FILED	2013/25529							
REG-0037HK	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	HK	FILED	16100081.2					1212378	10-Jun-16	
REG-0037ID	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	ID	FILED	P00201502427					2016/06397	25-Nov-16	
REG-0037IL	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	IL	FILED	237768							
REG-0037JP	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	JP	GRANTED	2015-535891	6272880				2015-536301	21-Dec-15	
REG-0037JP2	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	JP	FILED	2017-253345							
REG-0037KR	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	KR	FILED	10-2015-7009045							
REG-0037MA	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	MA	FILED	38083							
REG-0037MX	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	MX	GRANTED	MX/a/2015/004460	356340					23-May-18	
REG-0037MY	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	MY	FILED	PI 2015000876							
REG-0037NG	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	NG	GRANTED	NG/PT/C/2015/1023	NG/PT/C/2015/1023					15-Aug-17	
REG-0037NZ	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	NZ	GRANTED	630596	630596					29-Aug-17	
REG-0037NZ2	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPORT SYNDROME	NZ	FILED	730856							

TRADE MARK

REEL: 006407 FRAME: 0449

CONFIDENTIAL



Regulus Patent Portfolio  
July 26, 2018

REG-00370A	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	OA	GRANTED	1201500104	17284	30-Oct-15		
REG-0037PA	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	PA	FILED	90637			20-Nov-15	
REG-0037PH	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	PH	FILED	1-2015-500781				
REG-0037PK	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	PK	FILED	685/2013				
REG-0037SG	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	SG	GRANTED	11201502748R	11201502748R	19-Oct-16		
REG-0037TH	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	TH	FILED	1501001902			21-Jun-18	
REG-0037TN	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	TN	GRANTED	1501001902	24364	1-Sep-16	29-Jun-16	
REG-0037TW	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	TW	FILED	102136388			7-Jul-14	
REG-0037UA	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	UA	GRANTED	a 2015 04453	116639	25-Apr-18		
REG-0037US	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	US	GRANTED	14/048,827	9,012,423	21-Apr-15	10-Apr-14	
REG-0037US3	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	US	GRANTED	14/677,387	9,359,609	7-Jun-16	22-Oct-15	
REG-0037US4	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	US	GRANTED	15/151,290	9,688,986	27-Jun-17	3-Nov-16	
REG-0037US5	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	US	GRANTED	15/606,554	9,970,011	15-May-18	28-Dec-17	
REG-0037US6	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	US	FILED	15/948,450				
REG-0037UY	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	UY	FILED	35.069			30-Apr-14	
REG-0037VE	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	VE	FILED	1261-2013			15-Oct-14	
REG-0037ZA	8-Oct-13	9-Oct-12	METHODS FOR TREATMENT OF ALPURT SYNDROME	ZA	GRANTED	2015/02087	2015/02087	29-Jun-16		
REG-0038AU	30-Apr-14	1-May-13	MICRONA COMPOUNDS AND METHODS FOR MODULATING MIR-122	AU	FILED	2014259954				
REG-0038BR	30-Apr-14	1-May-13	MICRONA COMPOUNDS AND METHODS FOR MODULATING MIR-122	BR	FILED	BR 11 2015 027370 0			5-Sep-17	
REG-0038CA	30-Apr-14	1-May-13	MICRONA COMPOUNDS AND METHODS FOR MODULATING MIR-122	CA	FILED	2908939				
REG-0038CN	30-Apr-14	1-May-13	MICRONA COMPOUNDS AND METHODS FOR MODULATING MIR-122	CN	FILED	201480023247.3			2-Mar-16	

TRADE MARK

REEL: 006407 FRAME: 0450

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0038EA	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	EA	FILED	201592081				30-Jun-16
REG-0038EG	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	EG	FILED	1634/2015				
REG-0038EP	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	EP	FILED	14729529.9				
REG-0038HK	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	HK	FILED	16109285.7		1221256		26-May-17
REG-0038IL	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	IL	FILED	241957				
REG-0038IN	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	IN	FILED	10655/DELNP/2015				
REG-0038JP	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	JP	FILED	2016-512010		2016-518842		30-Jun-16
REG-0038KR	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	KR	FILED	10-2015-7031078				
REG-0038MX	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	MX	FILED	MX/a/2015/014816				
REG-0038NZ	8-Oct-13	9-Oct-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	NZ	GRANTED	630890	630890		4-Jan-18	
REG-0038NZ	8-Oct-13	9-Oct-12	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	NZ	FILED	732101				
REG-0038PK	2-May-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	PK	FILED	353/2014				
REG-0038SG	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	SG	GRANTED	11201508925W	11201508925W		14-May-18	
REG-0038SG2	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	SG	FILED	10201803157X		10201803157X		30-May-18
REG-0038TW	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	TW	FILED	103115662		201446791		16-Dec-14
REG-0038US	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	US	GRANTED	14/266.136	9,309,513	2014-0350090	12-Apr-16	27-Nov-14
REG-0038US2	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	US	GRANTED	14/577,481	9,157,083	2015-0105449	13-Oct-15	16-Apr-15
REG-0038US3	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	US	GRANTED	15/056,534	9,574,194	2016-0251657	21-Feb-17	1-Sep-16
REG-0038US4	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	US	FILED	15/403,672		2017-0218371		3-Aug-17
REG-0038ZA	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	ZA	FILED	2015/08097				
REG-0039AU	30-Apr-14	1-May-13	MICRORNA COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	AU	FILED	2014259953				

TRADEMARK

REEL: 006407 FRAME: 0451

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0039CA	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	CA	FILED	2909868							
REG-0039CN	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	CN	FILED	201480024094.4						CN 105164261 A	16-Dec-15
REG-0039EP	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	EP	FILED	14730641.9						2992096	9-Mar-16
REG-0039HK	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	HK	FILED	16109309.9						1221257	26-May-17
REG-0039IL	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	IL	FILED	241973							
REG-0039JP	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	JP	FILED	2016-512009						2016-518841	30-Jun-16
REG-0039NZ	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	NZ	GRANTED	630921							
REG-0039NZ2	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	NZ	FILED	734877							
REG-0039TW	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	TW	FILED	103115652						201505657	16-Feb-15
REG-0039US	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	US	GRANTED	14/266,127	9,506,030					2015-0031130	29-Jan-15
REG-0039US2	30-Apr-14	1-May-13	COMPOUNDS AND METHODS FOR ENHANCED CELLULAR UPTAKE	US	FILED	15/295,646						2017-0096668	6-Apr-17
REG-0040EP	23-Oct-14	25-Oct-13	MICORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	EP	FILED	14802966.3						3060664	31-Aug-16
REG-0040US	23-Oct-14	25-Oct-13	MICORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	GRANTED	15/029,535	9,994,846					2016-0333341	17-Nov-16
REG-0040US2	23-Oct-14	25-Oct-13	MICORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY	US	FILED	15/976,060							
REG-0043AU	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	AU	FILED	2015301057							
REG-0043BN	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	BN	FILED								
REG-0043BR	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	BR	FILED	BR 11 2017 001931-0							28-Nov-17
REG-0043CA	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	CA	FILED	2953883							
REG-0043CL	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	CL	FILED	201700312							6-Oct-17
REG-0043CN	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	CN	FILED	201580039229.9						CN 106559995	5-Apr-17
REG-0043CO	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	CO	FILED	NC2017/0000950							30-Jun-17

TRADE MARK

REEL: 006407 FRAME: 0452

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0043EP	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	EP	FILED	15750573.6			3177721	14-Jun-17
REG-0043GC	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	GC	FILED	2015/29851				
REG-0043HK	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	HK	FILED	17112763.1			1238678	4-May-18
REG-0043ID	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	ID	FILED	P00201701350			2018/01567	16-Feb-18
REG-0043IL	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	IL	FILED	249819				
REG-0043IN	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	IN	FILED	201717004031			201717004031A	14-Apr-17
REG-0043JP	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	JP	FILED	2017-506667			2017-523790	24-Aug-17
REG-0043KR	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	KR	FILED	10-2017-7005873				
REG-0043MX	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	MX	FILED	MX/a/2017/001493				
REG-0043MY	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	MY	FILED	PI 2017700393				
REG-0043NZ	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	NZ	FILED	727779				
REG-0043RU	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	RU	FILED	2017105342				
REG-0043SG	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	SG	FILED	11201610877P				
REG-0043TW	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	TW	FILED	104125684			201613949	16-Apr-16
REG-0043US	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	US	GRANTED	14/819,648	9,487,783		2016-0046940	18-Feb-16
REG-0043US2	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	US	GRANTED	15/272,619	9,862,950		2017-0067051	9-Mar-17
REG-0043US3	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	US	FILED	15/725,843			2018-0171334	21-Jun-18
REG-0043ZA	6-Aug-15	7-Aug-14	TARGETING MICRORNAS FOR METABOLIC DISORDERS	ZA	FILED	2017/00877				
REG-0047US	21-Feb-18	4-Sep-14	METHODS FOR DIRECT MEASUREMENT OF MICRORNA INHIBITION	US	FILED	15/754,061				
REG-0005GC	4-Dec-17	5-Dec-16	COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE	GC	FILED	34378				
REG-00053TW	4-Dec-17	5-Dec-16	COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE	TW	FILED	106142317			201821618	16-Jun-18

TRADE MARK

REEL: 006407 FRAME: 0453

CONFIDENTIAL

Regulus Patent Portfolio  
July 26, 2018

REG-0053WO	4-Dec-17	5-Dec-16	COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE	WO	FILED	PCT/US2017/064428			WO 2018/106566	14-Jun-18
REG-0061WO	4-May-18	4-May-17	METHODS FOR TREATMENT OF ALPORT SYNDROME	PCT	FILED	PCT/US2018/031094				
REG-0062US.L	8-May-18	8-May-18	MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122	US	FILED	62/668,467				
REG-0063US.L	20-Jul-18	20-Jul-18	ORAL DELIVERY OF MODIFIED OLIGONUCLEOTIDES	US	FILED	62/701,317				

*Please see attached*

Trademarks

EXHIBIT C

Trademark	Matter Number Country	SubCase Case Type	Status Classes	Application Number/Date	Registration Number/Date
REGULUS	35263 United States of America	ORD	Registered 05 Int., 42 Int.	87/441,064 08-May-2017	5,354,626 12-Dec-2017
	<b>Goods:</b> 05 Int. 42 Int.			Oligonucleotide preparations for therapeutic pharmaceutical purposes Research and development of oligonucleotides	
REGULUS & CIRCLE DESIGN	34719 United States of America	ORD	Published 05 Int., 42 Int.	87/028,238 06-May-2016	
	<b>Goods:</b> 05 Int. 42 Int.			Oligonucleotide preparations for therapeutic pharmaceutical purposes for a wide variety of conditions Research and development of oligonucleotides	
REGULUS MICROMARKERS	33715 United States of America	1 ORD	Registered 42 Int.	86/980,658 13-Jan-2014	5,102,108 13-Dec-2016
	<b>Goods:</b> 42 Int.			Scientific research and development; pharmaceutical research and development; research and development in the medical field; medical laboratory services; medical testing services for scientific research purposes; providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; consulting services in the fields of biotechnology and medical, pharmaceutical, and scientific research and development	
REGULUS THERAPEUTICS	33770 European Union (Community)	ORD	Registered 05 Int., 16 Int., 44 Int.	6910814 13-May-2008	CTM 6910814 20-Feb-2009
	<b>Goods:</b> 05 Int. 16 Int. 44 Int.			Pharmaceuticals. Educational and information materials in the field of pharmaceuticals. Information and advisory services relating to pharmaceuticals, including such services provided online from a computer network or the Internet; medical information services, namely providing information about pharmaceutical treatments; medical evaluation and monitoring services; biomedical services; diagnostic testing, self testing, self monitoring and adverse drug reaction testing services; medical services; advisory, consultative and telephone helpline services relating to the use of pharmaceuticals; technical help and support services provided by telephone or electronic mail and relating to the use of pharmaceuticals.	
REGULUS THERAPEUTICS	33779 United States of America	1 ORD	Registered 05 Int.	85/983,685 22-Jun-2012	4,795,763 18-Aug-2015
	<b>Goods:</b> 05 Int.			Pharmaceutical preparations and substances for the treatment of kidney diseases or disorders	
REGULUS THERAPEUTICS	33779 United States of America	3 ORD	Published 05 Int.	87/285,492 30-Dec-2016	

Trademark	Matter Number Country	SubCase Case Type	Status Classes	Application Number/Date	Registration Number/Date
	<b>Goods:</b> 05 Int.	Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, and diabetes			
REGULUS THERAPEUTICS (& STAR DESIGN)	33774 European Union (Community)	ORD	Registered 05 Int., 42 Int., 44 Int.	8988453 29-Mar-2010	CTM 8988453 29-Sep-2011
	<b>Goods:</b> 05 Int.	Pharmaceuticals for the treatment of infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of viral, metabolic, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological, muscular, fibrotic and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue			
	42 Int.	Research and development and consulting services relating to the treatment of infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of viral, metabolic, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological, muscular, fibrotic and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue			
	44 Int.	Medical testing for diagnostic or treatment purposes; medical services, namely treatment of human diseases and disorders; medical consulting services in the field of treating human diseases and disorders			
REGULUS THERAPEUTICS (& STAR DESIGN)	33775 Switzerland	ORD	Registered 05 Int., 42 Int., 44 Int.	604552 29-Mar-2010	604552 31-Aug-2010
	<b>Goods:</b> 05 Int.	Pharmaceuticals for the treatment of infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of viral, metabolic, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological, muscular, fibrotic and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue			
	42 Int.	Research and development relating to the treatment of infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of viral, metabolic, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological, muscular, fibrotic and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue			
	44 Int.	Medical testing for diagnostic or treatment purposes; medical services, namely treatment of human diseases and disorders; consulting services relating to the treatment of infectious diseases, pain, inflammation, sepsis, alopecia and obesity, and for the treatment of viral, metabolic, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological, muscular, fibrotic and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue			
REGULUS THERAPEUTICS (& STAR DESIGN)	33772 United States of America	ORD	Registered 42 Int.	77/838,225 30-Sep-2009	4,422,167 22-Oct-2013



**Goods:** 42 Int.

Research and development of pharmaceuticals relating to the treatment of infectious diseases, inflammation, and obesity, and for the treatment of viral, metabolic, cardiovascular, oncological, neurological, and fibrotic related diseases and disorders and for the treatment of damaged tissue; Consulting services in the fields of pharmaceutical research and development

---